arrow
R

Roberto Pazo-Cid

Hospital Universitario Miguel Servet
H指数:30
被引数:9,431

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Letter to the Editor: further reply to Kahl et al. regarding ‘NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial’

致编辑的信:关于“NALIRIFOX与 nab-paclitaxel 和 gemcitabine 在老年初治转移性胰腺癌患者中的比较:关键性 NAPOLI 3 试验的亚组分析”的进一步回复给 Kahl 等人

2026-10-090
OAAI
Intravenous hyaluronidase-expressing oncolytic adenovirus with chemotherapy in metastatic pancreatic cancer: a randomized phase 2b trial

静脉注射表达透明质酸酶的溶瘤腺病毒联合化疗治疗转移性胰腺癌:一项随机IIb期试验

2026-09-300
PRE
Real-World Germline Testing Patterns and Clinical Implications of HRR-Associated Germline Variants in Pancreatic Ductal Adenocarcinoma

胰腺导管腺癌中HRR相关胚系变异的现实世界检测模式及其临床意义

Cancers
IF4.4
2026-08-110
OA
Response to Letter to the Editor: 'NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial'

对编辑来信的回应:'NALIRIFOX与nab-紫杉醇和吉西他滨在治疗初治转移性胰腺癌老年患者中的比较:关键性NAPOLI 3试验的亚组分析'

2026-07-010
OAAI
NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial

NALIRIFOX与nab-紫杉醇和吉西他滨在治疗初治转移性胰腺癌老年患者中的比较:NAPOLI 3关键试验的亚组分析

2026-02-120
OAAI
Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649

纳武利尤单抗联合化疗作为晚期胃、胃食管结合部及食管腺癌的一线治疗方案:CheckMate 649研究的5年随访结果

2026-02-110
PREAI
Claudin 18.2 expression in gastroesophageal adenocarcinoma: biomarker overlap and association with clinical outcomes in a European cohort

胃食管腺癌中Claudin 18.2的表达: 生物标志物重叠及其与欧洲队列临床结果的关联

2026-01-270
OAAI
CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1

CD40激动剂米他扎利单抗联合mFOLFIRINOX治疗未治疗转移性胰腺癌:OPTIMIZE-1研究中与结局相关的生物标志物

2025-10-070
OAAI
Real-world management and outcomes of patients with hepatocellular carcinoma treated with systemic therapy in Spain: a patient cohort from the RETUD gastrointestinal registry

西班牙接受全身治疗肝细胞癌患者的实际管理及预后:来自RETUD消化道登记研究的患者队列

2025-08-090
OA
Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: results from the NAPOLI 3 trial

与健康相关的生活质量和体力状态:NALIRIFOX与nab-paclitaxel + gemcitabine在治疗初治的转移性胰腺导管腺癌患者中的比较:NAPOLI 3试验结果

2025-08-050
OAAI
First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305

一线Tislelizumab联合化疗治疗程序性死亡配体1表达 ≥ 1% 的晚期胃癌: 原理305的回顾性分析

2025-03-010
OAAI
Real-world effectiveness and safety of second- or third-line pegylated liposomal irinotecan plus 5-fluorouracil and folinic acid in pancreatic ductal adenocarcinoma in Spain
2025-01-080
OAAI
Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) + CT in HER2-negative advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GC/GEJC): RATIONALE-305 study minimum 3-year survival follow-up

替雷利珠单抗(TIS)联合化疗(CT)对比安慰剂(PBO)联合化疗(CT)治疗HER2阴性晚期或转移性胃或胃食管结合部腺癌(GC/GEJC):RATIONALE-305研究至少3年生存随访

2024-09-014
PRE
Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study
LANCET
IF88.5
2024-08-018
PRE
the TEOGIC study project: a comprehensive characterization of early onset gastrointestinal cancer in the Northern area of Spain (vol 24, pg 668, 2024)
2024-07-090
OAAI
The TEOGIC study project: a comprehensive characterization of early onset gastrointestinal cancer in the Northern area of Spain
2024-06-011
OAAI